Clinical trials: Carboplatin
Non-Small Cell Lung Cancer
Taxoprexin Plus Carboplatin Treatment for Advanced Lung Cancer
The primary objective of this trial is to compare the survival of patients with advanced non-small cell lung cancer (NSCLC) treated with weekly Taxoprexin in combination with carboplatin to those treated with paclitaxel plus…
- Trial name
- NCT00243867
- Testing
- Taxoprexin, Carboplatin, Paclitaxel
- Where
- United States
- Volunteers
- 518 people
- Sponsor
- American Regent, Inc.
Non-small Cell Lung Cancer
A Study of Pemetrexed, Carboplatin and Bevacizumab in Participants With Nonsquamous Non-Small Cell Lung Cancer
This study will compare overall survival in participants with Stage IIIB or IV nonsquamous non-small cell lung cancer.
- Trial name
- NCT00762034
- Testing
- Pemetrexed, Paclitaxel, Carboplatin
- Where
- 67 sites in United States
- Volunteers
- 939 people
- Sponsor
- Eli Lilly and Company
Lung Cancer, Small Cell
First-line Treatment Of Subjects With Extensive Disease Small Cell Lung Cancer With Weekly Hycamtin And Paraplatin
This study was designed to find the safest and most effective dose of a combination of two chemotherapy drugs, Hycamtin® (topotecan) and Paraplatin® (carboplatin), in people with extensive disease small cell lung cancer.
- Trial name
- NCT00316186
- Testing
- topotecan, carboplatin
- Where
- 13 sites in United States, Poland
- Volunteers
- 33 people
- Sponsor
- GlaxoSmithKline
Non-Squamous Non-Small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer
A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]
This randomized, open-label study will evaluate the efficacy and safety of atezolizumab compared with chemotherapy consisting of a platinum agent (cisplatin or carboplatin per investigator discretion) combined with either…
- Trial name
- NCT02409342
- Testing
- Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody, Carboplatin, Cisplatin
- Where
- 142 sites in United States, Brazil and 17 more
- Volunteers
- 572 people
- Sponsor
- Hoffmann-La Roche
Squamous Non Small Cell Lung Cancer
A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer
The main purpose of this study is to evaluate if necitumumab added to standard chemotherapy of paclitaxel and carboplatin is more effective to treat cancer than the standard chemotherapy of paclitaxel and carboplatin alone.
- Trial name
- NCT01769391
- Testing
- Necitumumab, Paclitaxel, Carboplatin
- Where
- 51 sites in United States, Germany and 4 more
- Volunteers
- 167 people
- Sponsor
- Eli Lilly and Company
Solid Tumor, Advanced Solid Tumor
First in Human Study of M4344 in Participants With Advanced Solid Tumors
The purpose of this study was to evaluate the safety and tolerability of multiple ascending doses of single-agent M4344 administered twice-weekly (BIW), twice daily (BID) or once daily dose schedule in participants with advanced…
- Trial name
- NCT02278250
- Testing
- M4344 10 mg BIW, M4344 20 mg BIW, M4344 40 mg BIW
- Where
- 16 sites in United States, Netherlands and 2 more
- Volunteers
- 97 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-Small-Cell Lung Cancer
A Study of Pemetrexed Plus Carboplatin, or Pemetrexed Plus Cisplatin With Radiation Therapy Followed by Pemetrexed in Patients With Inoperable Non-Small-Cell Lung Cancer
The primary purpose of this study is to determine the 2-year survival rate of both of the chemotherapy regimens in patients with inoperable non-small-cell lung cancer.
- Trial name
- NCT00482014
- Testing
- pemetrexed, cisplatin, carboplatin
- Where
- 11 sites in United States, India
- Volunteers
- 120 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
A Phase I, Open-Label, 2 Part Multicentre Study to Assess the Safety and Efficacy of Olaparib in Combination With Carboplatin in Patients With Advanced HER-2 Negative Breast Cancer
This is an open-label study to assess the safety, tolerability and efficacy of olaparib in combination with carboplatin. There are two parts in this study: Part A, a dose escalation in patients with advanced Human Epidermal…
- Trial name
- NCT02561832
- Testing
- Olaparib, Carboplatin, Anthracycline
- Where
- 7 sites in United States, Spain
- Volunteers
- 15 people
- Sponsor
- AstraZeneca
Stage IIIB or IV Non-Small Cell Lung Cancer
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)(0683-056)
This Phase III clinical trial which incorporates an initial Phase II component will determine the survival of advanced Non-small cell lung cancer patients when treated with MK0683 and paclitaxel plus carboplatin
- Trial name
- NCT00473889
- Testing
- vorinostat, Comparator: paclitaxel, Comparator: carboplatin
- Volunteers
- 253 people
- Sponsor
- Merck Sharp & Dohme LLC
Non-Small Cell Lung Cancer
A Study of Avastin (Bevacizumab) in Combination With Carboplatin-Based Chemotherapy in Patients With Advanced or Recurrent Non-Squamous Non-Small Cell Lung Cancer.
This study will explore the correlation of biomarkers with response rate, and the overall efficacy and safety, of Avastin in combination with carboplatin-based chemotherapy in patients with advanced or recurrent non-squamous…
- Trial name
- NCT00700180
- Testing
- bevacizumab [Avastin], Carboplatin-based chemotherapy
- Where
- 59 sites in Australia, Belgium and 14 more
- Volunteers
- 303 people
- Sponsor
- Hoffmann-La Roche
NSCLC (Non-small Cell Lung Cancer)
A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients
This is a Phase III, Randomized, Open-label, Efficacy and Safety Study of Crizotinib single agent versus Chemotherapy Regimens (Pemetrexed/Cisplatin or Pemetrexed/Carboplatin) in First-Line ALK (Anaplastic Lymphoma Kinase)…
- Trial name
- NCT01639001
- Testing
- Crizotinib, Pemetrexed/Cisplatin, Pemetrexed/Carboplatin
- Where
- 47 sites in China, Hong Kong and 3 more
- Volunteers
- 207 people
- Sponsor
- Pfizer
Lung Cancer - Non Small Cell Squamous
Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin
The purpose of the study is to determine whether Ipilimumab plus Paclitaxel and Carboplatin will extend the lives of patients with squamous only non small cell lung cancer more than placebo plus Paclitaxel and Carboplatin.
- Trial name
- NCT01285609
- Testing
- Ipilimumab, Paclitaxel, Carboplatin
- Where
- 290 sites in United States, Argentina and 34 more
- Volunteers
- 1,289 people
- Sponsor
- Bristol-Myers Squibb
Metastatic Breast Cancer
A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer
The primary objective of the study is to assess the progression-free survival (PFS) of veliparib in combination with carboplatin and paclitaxel (C/P) compared to placebo plus C/P in participants with a Breast Cancer Gene 1 or 2…
- Trial name
- NCT02163694
- Testing
- Veliparib, Carboplatin, Paclitaxel
- Where
- 219 sites in United States, Argentina and 35 more
- Volunteers
- 513 people
- Sponsor
- AbbVie
Carcinoma, Squamous Cell, Non-small-cell Lung
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
The current study will compare pembrolizumab (MK-3475) plus maintenance olaparib, vs. pembrolizumab plus maintenance olaparib placebo for the treatment of squamous NSCLC. The study's 2 primary hypotheses are: 1.
- Trial name
- NCT03976362
- Testing
- Pembrolizumab, Carboplatin, Paclitaxel
- Where
- 178 sites in United States, Argentina and 18 more
- Volunteers
- 851 people
- Sponsor
- Merck Sharp & Dohme LLC
Advanced Triple Negative Breast Cancer (TNBC) With High TAMs
Efficacy Study of MCS110 Given With Carboplatin and Gemcitabine in Advanced Triple Negative Breast Cancer (TNBC)
To determine whether MCS110 antibody therapy improves the efficacy of carboplatin and gemcitabine (carbo/gem) in advanced TNBC patients
- Trial name
- TNBC (NCT02435680)
- Testing
- MCS110, carboplatin, gemcitabine
- Where
- 23 sites in United States, Australia and 10 more
- Volunteers
- 50 people
- Sponsor
- Novartis Pharmaceuticals
Non-small Cell Lung Cancer
Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)
This is a multi-center, open-label, randomized, Phase 1b/2 study to determine the recommended phase 2 dose (RP2D) and to evaluate the efficacy in terms of progression free survival (PFS) of Tepotinib when used in combination with…
- Trial name
- NCT01982955
- Testing
- Tepotinib, Gefitinib, Pemetrexed
- Where
- 44 sites in China, Italy and 5 more
- Volunteers
- 88 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Non Small Cell Lung Cancer
Pemetrexed/Carboplatin Non-Small Cell Lung Cancer (NSCLC) Elderly Patients
A phase II study to evaluate the efficacy and safety profile of the combination of Pemetrexed and Carboplatin in elderly patients with advanced non-small cell lung cancer
- Trial name
- NCT00350792
- Testing
- pemetrexed, carboplatin
- Where
- 7 sites in France
- Volunteers
- 62 people
- Sponsor
- Eli Lilly and Company
Ovarian Cancer
Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse
This research is being done to find out if Carboplatin and Taxane works better alone or when given with an experimental drug called MORAb-003(farletuzumab) in subjects with first platinum sensitive relapsed ovarian cancer.
- Trial name
- NCT00849667
- Testing
- Farletuzumab, Carboplatin, Taxane
- Where
- 375 sites in United States, Argentina and 28 more
- Volunteers
- 1,100 people
- Sponsor
- Morphotek
Small Cell Lung Cancer (SCLC)
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)
The purpose of this study is to assess the safety and efficacy of pembrolizumab plus standard of care (SOC) chemotherapy (etoposide/platinum [EP]) in participants with newly diagnosed extensive stage small cell lung cancer…
- Trial name
- NCT03066778
- Testing
- Pembrolizumab, Normal saline solution, Carboplatin
- Where
- 148 sites in United States, Australia and 17 more
- Volunteers
- 453 people
- Sponsor
- Merck Sharp & Dohme LLC
Carcinoma, Non-Small-Cell Lung
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions
The purpose of this study is to compare the efficacy, as demonstrated by progression-free survival (PFS), in participants treated with amivantamab in combination with chemotherapy, versus chemotherapy alone in participants with…
- Trial name
- PAPILLON (NCT04538664)
- Testing
- Amivantamab, Pemetrexed, Carboplatin
- Where
- 232 sites in United States, Australia and 24 more
- Volunteers
- 308 people
- Sponsor
- Janssen Research & Development, LLC